Actualidad

/
/
New Study Evaluates the Utility of Masimo SpHb® Monitoring During Liver Transplantation

New Study Evaluates the Utility of Masimo SpHb® Monitoring During Liver Transplantation

13/03/2017

IRVINE, Calif.–(BUSINESS WIRE)–Mar. 13, 2017–
Masimo (NASDAQ:MASI)
announced today the publication of a recent study conducted on adult
patients undergoing liver transplantation (LT), in which researchers
assessed the accuracy and trending ability of noninvasive Masimo SpHb®
(total hemoglobin) measurement, as compared to conventional laboratory
hemoglobin (HbL) measurements. The researchers found that
SpHb had “clinically acceptable accuracy of hemoglobin measurement
[compared] with a standard laboratory device when used during LT” and
that “[t]his technology can be useful as a trend monitor during all
surgical phases o…

Más información: New Study Evaluates the Utility of Masimo SpHb® Monitoring During Liver Transplantation

Comparte:

El contenido de este sitio web está destinado únicamente a profesionales médicos/sanitarios.

Es posible que los productos contenidos en este sitio no estén disponibles en todos los mercados, ya que la disponibilidad está sujeta a prácticas normativas y médicas en mercados individuales.